CXC chemokine ligand 4 (CXCL4) is predictor of tumour angiogenic activity and prognostic biomarker in non-small cell lung cancer (NSCLC) patients undergoing surgical treatment

Artjoms Spaks (Coresponding Author), Darja Svirina, Irina Spaka, Inta Jaunalksne, Donats Breiva, Ilmars Tracums, Dainis Krievins

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)

Abstract

Objective: To evaluate the association of CXC chemokine ligand 4 (CXCL4) plasma levels with tumour angiogenesis in non-small cell lung cancer (NSCLC) and to assess association of CXCL4 with clinical outcomes. Patients and methods: Fifty patients with early stage NSCLC who underwent pulmonary resection. CXCL4 levels were analysed by ELISA. Angiogenesis was assessed by immunohistochemistry, and microvessel density (MVD) count. Results: There was positive correlation between MVD and CXCL4 levels. Patients with higher CXCL4 levels had worse overall and disease-free survival. Conclusions: Plasma levels of CXCL4 are associated with tumour vascularity. Increased CXCL4 levels in NSCLC patients undergoing treatment may indicate active cancer-induced angiogenesis associated with relapse and worse outcome.

Original languageEnglish
Pages (from-to)474-478
Number of pages5
JournalBiomarkers
Volume21
Issue number5
DOIs
Publication statusPublished - 3 Jul 2016
Externally publishedYes

Keywords

  • Angiogenesis
  • chemokines
  • CXC chemokine ligand 4
  • non-small cell lung cancer
  • platelet factor 4

Field of Science

  • 1.6 Biological sciences
  • 3.1 Basic medicine
  • 3.2 Clinical medicine

Publication Type

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database

Fingerprint Dive into the research topics of 'CXC chemokine ligand 4 (CXCL4) is predictor of tumour angiogenic activity and prognostic biomarker in non-small cell lung cancer (NSCLC) patients undergoing surgical treatment'. Together they form a unique fingerprint.

Cite this